These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29439329)

  • 21. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
    Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. APOEɛ4 Gene Dose and Sex Effects on Alzheimer's Disease MRI Biomarkers in Older Adults with Mild Cognitive Impairment.
    Hobel Z; Isenberg AL; Raghupathy D; Mack W; Pa J;
    J Alzheimers Dis; 2019; 71(2):647-658. PubMed ID: 31424388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alzheimer's disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology.
    Rembach A; Evered LA; Li QX; Nash T; Vidaurre L; Fowler CJ; Pertile KK; Rumble RL; Trounson BO; Maher S; Mooney F; Farrow M; Taddei K; Rainey-Smith S; Laws SM; Macaulay SL; Wilson W; Darby DG; Martins RN; Ames D; Collins S; Silbert B; Masters CL; Doecke JD;
    Alzheimers Res Ther; 2015 Nov; 7(1):71. PubMed ID: 26581886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease.
    Patra K; Soosaipillai A; Sando SB; Lauridsen C; Berge G; Møller I; Grøntvedt GR; Bråthen G; Begcevic I; Moussaud S; Minthon L; Hansson O; Diamandis EP; White LR; Nielsen HM
    Alzheimers Res Ther; 2018 Jan; 10(1):9. PubMed ID: 29378650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
    Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
    J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detecting At-Risk Alzheimer's Disease Cases.
    Fladby T; Pålhaugen L; Selnes P; Waterloo K; Bråthen G; Hessen E; Almdahl IS; Arntzen KA; Auning E; Eliassen CF; Espenes R; Grambaite R; Grøntvedt GR; Johansen KK; Johnsen SH; Kalheim LF; Kirsebom BE; Müller KI; Nakling AE; Rongve A; Sando SB; Siafarikas N; Stav AL; Tecelao S; Timon S; Bekkelund SI; Aarsland D
    J Alzheimers Dis; 2017; 60(1):97-105. PubMed ID: 28826181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty.
    Ruan Q; D'Onofrio G; Sancarlo D; Greco A; Yu Z
    Mol Med Rep; 2016 Oct; 14(4):3184-98. PubMed ID: 27511317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease.
    Lewczuk P; Popp J; Lelental N; Kölsch H; Maier W; Kornhuber J; Jessen F
    J Alzheimers Dis; 2012; 28(1):119-25. PubMed ID: 21971403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aβ1-17 is a major amyloid-β fragment isoform in cerebrospinal fluid and blood with possible diagnostic value in Alzheimer's disease.
    Pérez-Grijalba V; Pesini P; Allué JA; Sarasa L; Montañés M; Lacosta AM; Casabona D; San-José I; Boada M; Tárraga L; Ruiz A; Sarasa M
    J Alzheimers Dis; 2015; 43(1):47-56. PubMed ID: 25061046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia.
    Oikonomidi A; Tautvydaitė D; Gholamrezaee MM; Henry H; Bacher M; Popp J
    J Alzheimers Dis; 2017; 60(1):273-281. PubMed ID: 28826184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.
    Alexopoulos P; Werle L; Roesler J; Thierjung N; Gleixner LS; Yakushev I; Laskaris N; Wagenpfeil S; Gourzis P; Kurz A; Perneczky R;
    Alzheimers Res Ther; 2016 Dec; 8(1):51. PubMed ID: 27931251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multielectrode array analysis of cerebrospinal fluid in Alzheimer's disease versus mild cognitive impairment: a potential diagnostic and treatment biomarker.
    Görtz P; Siebler M; Ihl R; Henning U; Luckhaus C; Supprian T; Lange-Asschenfeldt C
    Biochem Biophys Res Commun; 2013 May; 434(2):293-7. PubMed ID: 23541573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease.
    Johansson P; Åberg D; Johansson JO; Mattsson N; Hansson O; Ahrén B; Isgaard J; Åberg ND; Blennow K; Zetterberg H; Wallin A; Svensson J
    Psychoneuroendocrinology; 2013 Sep; 38(9):1729-37. PubMed ID: 23473966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
    Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
    Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOEɛ4 Carriers.
    Starks EJ; Patrick O'Grady J; Hoscheidt SM; Racine AM; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Puglielli L; Asthana S; Dowling NM; Gleason CE; Anderson RM; Davenport-Sis NJ; DeRungs LM; Sager MA; Johnson SC; Bendlin BB
    J Alzheimers Dis; 2015; 46(2):525-33. PubMed ID: 25812851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.